Blanchette Rockefeller Neurosciences Institute, 8 Medical Center Drive, Morgantown, WV 26505, USA.
Blanchette Rockefeller Neurosciences Institute, 8 Medical Center Drive, Morgantown, WV 26505, USA.
Trends Pharmacol Sci. 2015 Jun;36(6):384-94. doi: 10.1016/j.tips.2015.04.004. Epub 2015 May 7.
Evidence is accumulating that many memory disorders, including those due to neurodegenerative diseases, traumatic brain injury (TBI), vascular disease, or abnormal brain development, share common features of memory-related pathology. Structural and functional deficits of synapses are at the core of the underlying pathophysiology, constituting a critical point of convergence in memory disorders. Memory therapeutics that target synaptic loss and dysfunction - that is, to slow, halt, or reverse progression of the disorders at the level of synapses, via synaptogenic molecular cascades such as those of protein kinase C (PKC) and brain-derived neurotrophic factor (BDNF) - possess universal therapeutic value for many forms of memory disorder. They may be useful either as standalone interventions for patients with memory disorders or as adjuncts to drugs that target the underlying pathology.
证据不断积累表明，许多记忆障碍，包括由神经退行性疾病、创伤性脑损伤（TBI）、血管疾病或异常大脑发育引起的记忆障碍，都具有与记忆相关病理的共同特征。突触的结构和功能缺陷是潜在病理生理学的核心，是记忆障碍中一个关键的汇聚点。以突触丧失和功能障碍为靶点的记忆治疗药物——即通过蛋白激酶 C（PKC）和脑源性神经营养因子（BDNF）等突触发生分子级联反应来减缓、阻止或逆转突触水平上的疾病进展——对许多形式的记忆障碍都具有普遍的治疗价值。它们可以作为记忆障碍患者的独立干预措施，也可以作为针对潜在病理的药物的辅助治疗。
